These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21265713)

  • 21. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy.
    Ko J; Park K; Kim YS; Kim MS; Han JK; Kim K; Park RW; Kim IS; Song HK; Lee DS; Kwon IC
    J Control Release; 2007 Nov; 123(2):109-15. PubMed ID: 17894942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
    Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
    J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin.
    Sadzuka Y; Sugiyama I; Tsuruda T; Sonobe T
    Int J Pharm; 2006 Apr; 312(1-2):83-9. PubMed ID: 16457972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T; Atobe K; Wang X; Kiwada H
    J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
    Amin M; Badiee A; Jaafari MR
    Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice].
    Xu XY; Zhou JP; Li L; Zhang Y; Huo MR; Wang X; Lü L
    Yao Xue Xue Bao; 2008 Jul; 43(7):743-8. PubMed ID: 18819480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells.
    Dai W; Yang T; Wang X; Wang J; Zhang X; Zhang Q
    J Drug Target; 2010 May; 18(4):254-63. PubMed ID: 19824864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
    Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
    Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doxorubicin-encapsulated thermosensitive liposomes modified with poly(N-isopropylacrylamide-co-acrylamide): drug release behavior and stability in the presence of serum.
    Han HD; Shin BC; Choi HS
    Eur J Pharm Biopharm; 2006 Jan; 62(1):110-6. PubMed ID: 16183268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.
    Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Owen DJ; Boyd BJ; Porter CJ
    J Control Release; 2011 Jun; 152(2):241-8. PubMed ID: 21315119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PEG-modified GoldMag nanoparticles (PGMNs) combined with the magnetic field for local drug delivery.
    Chao X; Guo L; Zhao Y; Hua K; Peng M; Chen C; Cui Y
    J Drug Target; 2011 Apr; 19(3):161-70. PubMed ID: 20465360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
    Han L; Huang R; Liu S; Huang S; Jiang C
    Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated magnetic nanocarriers for doxorubicin delivery: a quantitative determination of stealthiness in vitro and in vivo.
    Allard-Vannier E; Cohen-Jonathan S; Gautier J; Hervé-Aubert K; Munnier E; Soucé M; Legras P; Passirani C; Chourpa I
    Eur J Pharm Biopharm; 2012 Aug; 81(3):498-505. PubMed ID: 22510695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes.
    Han HD; Lee A; Song CK; Hwang T; Seong H; Lee CO; Shin BC
    Int J Pharm; 2006 Apr; 313(1-2):181-8. PubMed ID: 16540270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature.
    Herringson TP; Altin JG
    Int J Pharm; 2011 Jun; 411(1-2):206-14. PubMed ID: 21443937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyethylene sebacate-doxorubicin nanoparticles for hepatic targeting.
    Guhagarkar SA; Gaikwad RV; Samad A; Malshe VC; Devarajan PV
    Int J Pharm; 2010 Nov; 401(1-2):113-22. PubMed ID: 20854883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin.
    Talelli M; Iman M; Varkouhi AK; Rijcken CJ; Schiffelers RM; Etrych T; Ulbrich K; van Nostrum CF; Lammers T; Storm G; Hennink WE
    Biomaterials; 2010 Oct; 31(30):7797-804. PubMed ID: 20673684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes.
    Arima H; Hagiwara Y; Hirayama F; Uekama K
    J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
    Koide H; Asai T; Hatanaka K; Akai S; Ishii T; Kenjo E; Ishida T; Kiwada H; Tsukada H; Oku N
    Int J Pharm; 2010 Jun; 392(1-2):218-23. PubMed ID: 20227473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.